---
title: "Supernus and Indivior merge to create scaled, CNS-focused entity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294826245.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-04T10:57:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294826245.md)
  - [en](https://longbridge.com/en/news/294826245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294826245.md)
generator: "portal-rs"
---

# Supernus and Indivior merge to create scaled, CNS-focused entity

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [SUPN.US](https://longbridge.com/en/quote/SUPN.US.md)
- [INDV.US](https://longbridge.com/en/quote/INDV.US.md)
- [INDV.UK](https://longbridge.com/en/quote/INDV.UK.md)

## Related News & Research

- [Supernus Q2 FY26 net loss widens to $58.4 million; revenue rises 32% to $219.1 million](https://longbridge.com/en/news/294679432.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [Enrolment concludes in Lynch’s Phase II rhPDGF-BB study](https://longbridge.com/en/news/296343171.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**